Ipamorelin: The Selective Growth Hormone Releasing Peptide

Ipamorelin is one of the most searched peptides in the optimization medicine space, generating over 28,000 monthly searches from people seeking growth hormone support without the cost, complexity, and side effects of exogenous growth hormone therapy. Its appeal is straightforward: ipamorelin stimulates your body's own growth hormone production through a remarkably clean mechanism that avoids the cortisol spikes, prolactin elevation, and intense hunger that plague other growth hormone secretagogues.

While we have a comprehensive guide on the CJC-1295/Ipamorelin combination, this page covers ipamorelin as a standalone compound: what it is, how it works, what makes it different from other GHRPs, and where it stands in the current regulatory landscape. We do not provide dosing information. Growth hormone peptide therapy should only be pursued under the supervision of a licensed physician who can evaluate your individual situation, order appropriate bloodwork, and monitor your response. For an overview of how peptide therapy works, see our hormone optimization guide.

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide, a chain of five amino acids, that belongs to the class of compounds known as growth hormone releasing peptides (GHRPs). It was first described in the scientific literature in 1998 by researchers at Novo Nordisk, the same Danish pharmaceutical company that later developed semaglutide. Ipamorelin was designed to be a highly selective growth hormone secretagogue, one that could stimulate the pituitary gland to release growth hormone while minimizing the off-target effects that limited the clinical utility of earlier GHRPs.

To understand what makes ipamorelin special, it helps to understand the two natural pathways through which the body stimulates growth hormone release:

• The GHRH pathway. Growth hormone releasing hormone (GHRH) is produced by the hypothalamus and acts on the anterior pituitary through the GHRH receptor. It provides the primary stimulatory signal for GH release. Peptides that mimic this pathway include sermorelin and CJC-1295.
• The ghrelin pathway. Ghrelin, the “hunger hormone,” also stimulates GH release by acting on the growth hormone secretagogue receptor (GHS-R, also called the ghrelin receptor) on the pituitary. This is a separate pathway from GHRH. Peptides that activate this pathway are called GHRPs, and they include GHRP-6, GHRP-2, hexarelin, and ipamorelin.

These two pathways work synergistically: activating both simultaneously produces a greater GH release than either pathway alone, which is the rationale behind combining a GHRH analog (like CJC-1295) with a GHRP (like ipamorelin). But within the GHRP class, not all compounds are created equal. Earlier GHRPs like GHRP-6 and GHRP-2 are effective at stimulating GH release but also activate other pathways, causing unwanted effects.

Ipamorelin was specifically engineered to address these limitations. Through careful structure-activity optimization, researchers at Novo Nordisk created a GHRP that maintained robust GH-releasing activity while dramatically reducing the off-target effects that made other GHRPs problematic. The result was a compound that the researchers described as the first truly selective GHRP.

How ipamorelin works

Ipamorelin activates the GHS-R (growth hormone secretagogue receptor) on somatotroph cells in the anterior pituitary gland. Somatotrophs are the specific pituitary cells that produce and store growth hormone. When the GHS-R is activated, these cells release stored GH into the bloodstream in a pulse, mimicking the natural pulsatile pattern of GH secretion.

Growth hormone release.Ipamorelin produces a dose-dependent increase in circulating growth hormone levels. The GH response follows a pulsatile pattern: levels rise within minutes of administration, peak at approximately 20-40 minutes, and return to baseline within 2-3 hours. This pulsatile release is more physiological than the sustained elevation produced by exogenous growth hormone injection, which is important because the body's tissues respond to GH pulses differently than to sustained GH exposure.

Selectivity: what ipamorelin does not do. This is where ipamorelin truly distinguishes itself. In research studies directly comparing ipamorelin to other GHRPs:

• Cortisol. GHRP-6 and GHRP-2 both produce significant increases in cortisol, the body's primary stress hormone. Elevated cortisol can promote fat storage, muscle breakdown, immune suppression, and sleep disruption, which directly counteracts many of the goals that people pursue GH therapy for in the first place. Ipamorelin produces no significant increase in cortisol at doses that effectively stimulate GH release.
• Prolactin. Several GHRPs increase prolactin, a hormone that in excess can cause mood changes, sexual dysfunction, and in men, gynecomastia. GHRP-2 and hexarelin both raise prolactin. Ipamorelin does not produce clinically significant prolactin elevation.
• Appetite. GHRP-6 is notorious for causing intense, almost irresistible hunger within minutes of administration. This is because it strongly activates the ghrelin signaling pathway that drives appetite. Ipamorelin, despite acting on the same receptor, produces minimal appetite stimulation. The mechanism of this differential effect is not fully understood but may relate to biased agonism, where the compound preferentially activates certain intracellular signaling pathways over others when binding to the same receptor.
• ACTH. Adrenocorticotropic hormone (ACTH) stimulates cortisol production from the adrenal glands. Some GHRPs increase ACTH, which is one mechanism through which they raise cortisol. Ipamorelin does not significantly affect ACTH levels.

The net result is a compound that delivers the desired effect, pulsatile growth hormone release, with a remarkably clean side effect profile. This selectivity is why ipamorelin became the GHRP of choice in the optimization medicine community and why it generates more search volume than any other single growth hormone peptide.

Research and evidence

Ipamorelin has been studied in both animal models and human subjects, with research spanning its GH-releasing properties, selectivity profile, and potential therapeutic applications.

Growth hormone release studies

The foundational research by Raun and colleagues at Novo Nordisk, published in 1998, characterized ipamorelin's GH-releasing properties in detail. Using both in vitro (cell-based) and in vivo (whole animal) models, they demonstrated that ipamorelin produced dose-dependent GH release comparable in magnitude to GHRP-6 but without the ACTH, cortisol, or prolactin effects. In rats, ipamorelin administration produced GH peaks of similar magnitude to GHRP-6 across a range of doses, while GHRP-6 caused parallel increases in cortisol and ACTH that were absent with ipamorelin.

Human studies confirmed this selectivity profile. When administered to healthy volunteers, ipamorelin produced robust, dose-dependent GH release with no significant effects on cortisol, prolactin, FSH, LH, or TSH at doses that effectively stimulated growth hormone. This clean profile in human subjects was consistent with the preclinical findings and supported ipamorelin's characterization as the first selective GHRP.

Bone and recovery studies

Ipamorelin has been studied in the context of bone health and post-surgical recovery. Research in animal models of osteoporosis demonstrated that ipamorelin administration increased bone mineral density and improved bone strength markers, consistent with the known anabolic effects of growth hormone on bone tissue. A Phase 2 clinical trial evaluated ipamorelin for the recovery of bowel function following abdominal surgery, based on the rationale that GH signaling can promote gastrointestinal motility and recovery.

The broader body of evidence supporting GH secretagogue therapy is relevant here, as the effects of ipamorelin-stimulated GH release are expected to mirror the well-characterized effects of growth hormone on body composition, recovery, sleep quality, skin health, and metabolic function. The advantage of stimulating endogenous GH release over administering exogenous GH is that the body's natural feedback mechanisms remain intact, and the pulsatile pattern of release more closely mimics normal physiology.

The selectivity question

Why ipamorelin is so much more selective than other GHRPs acting on the same receptor is not fully resolved. The GHS-R receptor exhibits what pharmacologists call functional selectivity or biased agonism: different ligands binding to the same receptor can activate different intracellular signaling cascades. GHRP-6 and ipamorelin both bind GHS-R, but they appear to stabilize different receptor conformations that preferentially activate different downstream pathways. Ipamorelin appears to preferentially activate the pathways leading to GH release while minimally engaging the pathways that drive cortisol, prolactin, and appetite signaling.

This biased agonism concept is increasingly recognized across pharmacology and explains how two drugs targeting the same receptor can have very different clinical profiles. For ipamorelin, the practical result is a compound that delivers the benefits of ghrelin receptor activation for GH release while largely avoiding the unwanted effects of full ghrelin pathway activation.

Ipamorelin compared to other GH peptides

The growth hormone peptide landscape includes several categories of compounds, and understanding where ipamorelin fits helps patients and physicians make informed choices.

Versus GHRP-6.GHRP-6 was one of the earliest GHRPs and remains available in some contexts. It produces strong GH release but also significant appetite stimulation, cortisol elevation, and prolactin increase. GHRP-6 may be appropriate for patients who need appetite stimulation (such as those recovering from illness), but for most optimization medicine applications, ipamorelin's cleaner profile is preferred.

Versus GHRP-2. GHRP-2 is more selective than GHRP-6 but less selective than ipamorelin. It produces some cortisol and prolactin elevation, though less than GHRP-6. It also causes moderate appetite stimulation. GHRP-2 may produce slightly more GH release than ipamorelin at equivalent doses in some studies, but the trade-off is the additional side effects.

Versus sermorelin. Sermorelin works through a completely different pathway, the GHRH receptor rather than the ghrelin receptor. It is a GHRH analog, not a GHRP. Sermorelin produces GH release through the same receptor as natural GHRH, with a profile that is highly physiological but sometimes less potent than GHRPs. Currently, sermorelin holds a significant regulatory advantage: it is Category 1 and can be legally compounded and prescribed.

Versus the CJC-1295/ipamorelin combination. The CJC-1295/ipamorelin stackcombines GHRH pathway activation (CJC-1295) with ghrelin pathway activation (ipamorelin). This dual activation produces synergistic GH release greater than either compound alone. The combination has been the most widely used GH peptide protocol in the optimization medicine community because it maximizes the GH pulse while leveraging ipamorelin's clean side effect profile.

Versus exogenous growth hormone (HGH).Direct growth hormone injection provides the most predictable and potent GH elevation but at significant cost (financial and physiological). Exogenous GH bypasses the pituitary entirely, can cause sustained supraphysiological GH levels rather than natural pulses, and carries risks including joint pain, carpal tunnel syndrome, insulin resistance, and potential effects on tumor growth. Ipamorelin and other secretagogues work within the body's natural regulatory framework, which provides a more conservative approach with a better safety profile for most optimization applications.

Legal status in 2026

Ipamorelin is currently classified as a Category 2 peptide in the United States, which means it cannot be legally compounded by pharmacies or prescribed through standard compounding channels. This classification is the same one that applies to BPC-157, TB-500, and several other popular peptides. It is not a controlled substance, but compounding pharmacies cannot legally produce it under current regulations.

RFK's February 27, 2026 announcement indicated that several peptides are expected to be reclassified from Category 2 to Category 1, which would restore legal access through licensed compounding pharmacies with a physician's prescription. The formal FDA publication specifying exactly which peptides will be reclassified is pending. Ipamorelin is widely expected to be included given its extensive use history and favorable safety profile, but until the formal publication occurs, its Category 2 status remains in effect.

For a complete understanding of the Category 1/Category 2 system and the reclassification process, see our comprehensive guide on whether peptides are legal in 2026.

In the interim, patients interested in growth hormone optimization have several legally available options. Sermorelin is a Category 1 GHRH analog that can be legally prescribed and compounded today. While it works through a different receptor than ipamorelin, it provides legitimate, physician-supervised GH stimulation through proper medical channels. Discussing your GH optimization goals with a physician experienced in peptide therapy is the appropriate first step regardless of the regulatory timeline.

Safety profile

Ipamorelin's safety profile is one of its strongest attributes. In published research and extensive clinical use prior to the Category 2 reclassification, ipamorelin has demonstrated an excellent tolerability profile. The absence of cortisol, prolactin, and significant appetite effects removes many of the safety concerns associated with other GHRPs.

Reported side effects in clinical use have been generally mild and include occasional headache, transient flushing, and injection site reactions. These are typical of peptide therapies broadly and are not specific to ipamorelin. The compound does not appear to produce the water retention, joint pain, or insulin resistance that can occur with exogenous growth hormone therapy, likely because the GH pulses it produces remain within physiological parameters rather than creating sustained supraphysiological levels.

However, several important considerations apply. Growth hormone secretagogues of any type should be used with caution in patients with active malignancy, as GH and IGF-1 can promote tumor growth. Patients with diabetes or significant insulin resistance should be monitored closely, as GH has complex effects on glucose metabolism. Long-term safety data from formal clinical trials is limited, and the safety of chronic use over years or decades has not been systematically established.

Physician supervision is essential for appropriate patient selection, baseline and monitoring bloodwork (including IGF-1, fasting glucose, and insulin), and ongoing assessment of therapeutic response. Growth hormone peptide therapy is not a self-guided endeavor. A qualified physician can determine whether GH optimization is appropriate for your specific situation and can select the right compound and monitoring protocol for your needs.

Frequently asked questions

What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor. It is the most selective growth hormone releasing peptide (GHRP), meaning it stimulates GH release without the cortisol elevation, prolactin increase, and appetite stimulation that occur with other GHRPs like GHRP-6. Developed by Novo Nordisk and first published in 1998, it has become one of the most widely used growth hormone peptides in optimization medicine.

What is the difference between ipamorelin and GHRP-6?

Both activate the ghrelin receptor to stimulate GH release, but GHRP-6 also significantly increases appetite, cortisol, and prolactin, while ipamorelin does not. Ipamorelin achieves comparable GH release with a much cleaner side effect profile. GHRP-6 may be preferred when appetite stimulation is desired, but for most optimization applications, ipamorelin's selectivity makes it the preferred GHRP.

Is ipamorelin legal?

Ipamorelin is currently classified as a Category 2 peptide in the United States, meaning it cannot be legally compounded by pharmacies. It is not a controlled substance. Reclassification to Category 1, which would restore legal access, is expected as part of the ongoing regulatory process following RFK's February 2026 announcement, but the formal FDA publication is pending. Sermorelin is a legally available Category 1 alternative for growth hormone optimization.

Can I stack ipamorelin with CJC-1295?

The CJC-1295/ipamorelin combination is the most well-known growth hormone peptide stack. CJC-1295 activates the GHRH receptor while ipamorelin activates the ghrelin receptor. Activating both pathways produces synergistic GH release greater than either compound alone. This combination is covered in detail in our CJC-1295/Ipamorelin guide. Both peptides are currently Category 2, and any use should be under physician supervision.

Does ipamorelin increase appetite?

Unlike GHRP-6, which causes intense hunger, ipamorelin produces minimal appetite stimulation despite acting on the same ghrelin receptor. This selectivity is one of ipamorelin's primary advantages and a key reason for its popularity. The mechanism likely involves biased agonism, where ipamorelin activates the GH-releasing pathways of the ghrelin receptor while minimally engaging the appetite-stimulating pathways. Most patients report little to no change in hunger patterns with ipamorelin.